《大行報告》麥格理下調歐舒丹(00973.HK)目標價至34.6元 評級「跑贏大市」
麥格理髮表報告指,歐舒丹(00973.HK)公佈2023財年上半年業績,收入按年增29.3%至9.01億歐元,高於該行預測的13.9%,純利按年增5.4%至6,400萬歐元,低於該行預測的15%,若排除俄羅斯業務一次性的資產剝離,指營運利潤則符合該行預測。
該行表示,調整歐舒丹2023年及2024年盈利預測爲降0.6%及升2%,並將歐舒丹目標價由38.2元下調至34.6元,重申「跑贏大市」評級。(ca/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.